Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.

@article{Simonds1995ProphylaxisAP,
  title={Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.},
  author={Robert J Simonds and Mary Lou Lindegren and Peter O. Thomas and Daniel A. Hanson and Blake Caldwell and Gwendolyn Scott and Miriam P Rogers},
  journal={The New England journal of medicine},
  year={1995},
  volume={332 12},
  pages={786-90}
}
BACKGROUND Pneumocystis carinii pneumonia (PCP) remains a common and often fatal opportunistic infection among children infected with the human immunodeficiency virus (HIV). HIV-infected infants between three and six months of age are particularly vulnerable. Current guidelines recommend prophylaxis in children from birth to 11 months old who have CD4… CONTINUE READING